WHO grants Emergency Use Listing status for Covaxin

The TAG-EUL is an independent advisory group that provides recommendations to WHO on whether a COVID-19 vaccine can be listed for emergency use under the EUL procedure

The World Health Organisation (WHO) on Wednesday granted emergency use listing for Bharat Biotech COVID-19 vaccine Covaxin.

"WHO has granted emergency use listing (EUL) to COVAXIN (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of COVID19.

"The Technical Advisory Group, convened by WHO and made up of regulatory experts from around the world, has determined that the Covaxin vaccine meets WHO standards for protection against COVID-19, that the benefit of the vaccine far outweighs risks & the vaccine can be used," the organisation tweeted.

The organisation added that the vaccine should be administered in two doses, with a dose interval of four weeks, in all age groups 18 and above.

"Covaxin vaccine was also reviewed by WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), and recommended use of this vaccine in two doses, with a dose interval of four weeks, in all age groups 18 and above.

"Available data on vaccination of pregnant women with the Covaxin vaccine are insufficient to assess vaccine safety or efficacy in pregnancy; studies in pregnant women are planned, including a pregnancy sub-study and a pregnancy registry," the organisation tweeted.

The TAG-EUL is an independent advisory group that provides recommendations to WHO on whether a COVID-19 vaccine can be listed for emergency use under the EUL procedure.

Covaxin has demonstrated 77.8% effectiveness against symptomatic COVID-19 and 65.2% protection against the new Delta variant.

In June, the company said it concluded the final analysis of Covaxin efficacy from Phase 3 trials.

Bharat Biotech’s Covaxin and AstraZeneca and Oxford University’s Covishield are the two widely used vaccines in India.

(Inputs from PTI)

Source: Read Full Article